Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults.
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2013
At a glance
- Drugs Malaria vaccine (Primary) ; Glycopyranosyl lipid adjuvant
- Indications Falciparum malaria
- Focus Adverse reactions
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Mar 2012 New trial record